NCT06015893View on ClinicalTrials.gov

Semaglutide Therapy for Alcohol Reduction (STAR)

PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 17, 2023

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
AddictionAlcohol Use Disorder
Interventions
BEHAVIORAL

Take Control

A computer-delivered behavioral therapy derived from the NIAAA s self-help approach, Rethinking Drinking, developed for use in pharmacotherapy trials.

DRUG

Semaglutide

Weekly subcutaneous (s.c.) injections of semaglutide (or placebo) up to 2.4 mg/week or maximum tolerated dose (MTD).

Trial Locations (1)

21224

RECRUITING

National Institute on Drug Abuse, Baltimore

All Listed Sponsors
lead

National Institute on Drug Abuse (NIDA)

NIH